BioArctic AB (STO:BIOAB), a research based biopharmaceutical company, on Tuesday reported profit of SEK15.2m, or EPS of SEK0.22, from January 2017 to December 2017.
This was a decline over profit of SEK57.6m, or EPS of SEK0.91, in 2016.
Net sales for the year amounted to SEK140.7m, as compared with SEK105.6m in 2016.
Also, the company's board of directors has proposed that that no dividend is paid for the financial year 2017.
BioArctic is focussed on disease modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company is also developing a treatment for complete spinal cord injury.
(EUR1.00=SEK9.99)
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Perrigo to pay quarterly dividend of USD0.290 per share
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline